An Evaluation of a Dynamic Web-Based Visualization of Community Immunity
NCT04787913 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5516
Last updated 2024-08-29
Summary
This study is a PhD project conducted by Ms. Hina Hakim, supervised by Dr. Holly O. Witteman, PhD, and co-supervised Dr. Daniel Reinharz, professors and researchers at the Faculty of Medicine at Laval University. The purpose of this study is to evaluate the effects of visualization conveying the concept of community immunity or herd immunity on risk perception (towards individual, family, community and vulnerable people in communities) (primary outcome) and on emotions, attitudes, knowledge, and behavioural intentions (secondary outcomes).
Conditions
- Vaccine-Preventable Diseases
Interventions
- BEHAVIORAL
-
herdimm
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
- BEHAVIORAL
-
guardianmeasles
A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
- BEHAVIORAL
-
theotheredmundmeasles
A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
- BEHAVIORAL
-
sbsnewsgeneric
A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
- BEHAVIORAL
-
publichealthagencycanadaflu
A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html
- BEHAVIORAL
-
robertkochgeneric
A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
Sponsors & Collaborators
-
Laval University
lead OTHER
Principal Investigators
-
Holly Witteman, PhD · Laval University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-03-01
- Primary Completion
- 2021-07-01
- Completion
- 2021-07-01
Countries
- Canada
Study Locations
More Related Trials
-
Surveillance for Adverse Events Following Influenza Immunization
NCT01318876 ·Status: COMPLETED
-
Surveillance for Adverse Events Following Pandemic H1N1 Immunization
NCT01289418 ·Status: COMPLETED
-
Health Management Training to Enhance Influenza Vaccine Immunogenicity
NCT01256515 ·Status: COMPLETED ·Phase: NA
-
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
NCT04794829 ·Status: COMPLETED
-
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
NCT00968539 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of a Brief Intervention for Acceptance of Influenza Vaccine in the Primary Care Setting
NCT04568785 ·Status: COMPLETED ·Phase: NA
-
Body and Social Behavior
NCT05654441 ·Status: COMPLETED ·Phase: PHASE4
-
Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts
NCT02284594 ·Status: COMPLETED ·Phase: NA
-
PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging
NCT01974050 ·Status: COMPLETED ·Phase: NA
-
Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults
NCT02401893 ·Status: COMPLETED
-
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age
NCT04144179 ·Status: COMPLETED ·Phase: PHASE1
-
Precision Vaccine Promotion in Underserved Populations
NCT05537441 ·Status: COMPLETED ·Phase: NA
-
Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions
NCT01431183 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals
NCT03816878 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11
NCT01206114 ·Status: COMPLETED
-
Effectiveness of SMS Nudging to Increase Coverage of Influenza Vaccination Among the Elderly
NCT06486766 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Heterosubtypic Immune Responses to Influenza in Older People
NCT00798343 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
NCT00457509 ·Status: COMPLETED ·Phase: PHASE1
-
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
NCT03688620 ·Status: COMPLETED ·Phase: PHASE4
-
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
NCT02307851 ·Status: COMPLETED ·Phase: PHASE2
-
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
NCT01342796 ·Status: COMPLETED ·Phase: PHASE2
-
Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department
NCT00380679 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
NCT00929331 ·Status: COMPLETED ·Phase: PHASE3
-
Personalized Nudging to Increase Influenza Vaccinations
NCT06566534 ·Status: COMPLETED ·Phase: NA
-
Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease
NCT06030739 ·Status: COMPLETED ·Phase: NA